Aliquot reconstituted peptide into single-use vials to maintain stability throughout multi-week experiments
Biogenic Foods Tesamorelin & Ipamorelin - 12mg/2mg *Phoenix Blend* - Research Peptide SKU: tes/ipa-12mg/2mg Weight: 2.00 Ounces Description Description CAS Number: N/A (research blend) Molecular Formula: N/A (research blend) Molecular Weight: N/A (research blend) Form: Lyophilized Powder Quantity: 12mg/2mg vial Purity: 98% (HPLC Verified) Product Overview: Tesamorelin/Ipamorelin (12mg/2mg) is a synergistic peptide blend pairing Tesamorelin, a synthetic growth hormonereleasing hormone (GHRH) analog, with Ipamorelin, a selective growth hormone secretagogue receptor (GHSR) agonist
Food and Drug Administration OPSS Athletes should avoid BPC157 due to WADA S0 prohibition and contamination risk which can result in anti doping violations even with claimed research only products
Water/Aqua/Eau, Glycerin, Propanediol, Squalane, Sodium Hyaluronate, Hydroxyethyl Acrylate/Sodium Acryloyldimethyl Taurate Copolymer, Copper Tripeptide-1, Acmella Oleracea Extract, Ectoin, Tetrapeptide-30, Palmitoyl Hexapeptide-52, Copper PCA, Panthenol, Sodium Polyglutamate, Camellia Sinensis Leaf Extract, Aloe Barbadensis Flower Extract, Passiflora Incarnata Flower Extract, Melia Azadirachta Leaf Extract, Solanum Melongena (Eggplant) Fruit Extract, Curcuma Longa (Turmeric) Root Extract, Ocimum Basilicum (Basil) Flower/Leaf Extract, Coccinia Indica Fruit Extract, Melia Azadirachta Flower Extract, Ocimum Sanctum Leaf Extract, Corallina Officinalis Extract, Polyacrylate Crosspolymer-6, Acacia Senegal Gum, Xanthan Gum, Phenoxyethanol, Ethylhexylglycerin, Citric Acid, Caprylyl Glycol For the latest information, it is recommended to review the ingredient list printed on the packaging of the product prior to usage or consumption
Aim for at least 810 cups of water daily, and consider adding a pinch of sea salt or an electrolyte tablet if youve been nauseous or have a lower appetite
"Effect of corticosteroid injection, physiotherapy, or both on clinical outcomes in patients with unilateral lateral epicondylalgia." JAMA
